Arrowhead Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with REDEMPLO already launched and multiple late-stage programs advancing. Key upcoming milestones include pivotal data for plozasiran and zodasiran, and first human data for the dual-targeting DIMER siRNA, all targeting significant unmet needs in hyperlipidemia and ASCVD.
-
The session highlighted a strategic shift toward commercial execution, with a focus on cardiometabolic diseases and upcoming pivotal data for Redemplo. Early commercial results are promising, with expanded patient identification and positive payer feedback. The pipeline includes innovative obesity and liver disease programs.
-
The company is advancing a robust siRNA pipeline, with pivotal data for plozasiran in SHTG expected in Q3 and strong commercial uptake for REDEMPLO. Obesity and CNS programs are progressing, with key updates and new cohorts planned for the second half of the year.
-
Recent regulatory approvals and strong commercial launch have positioned the company for significant growth, with key phase III trial readouts expected in Q3. The pipeline focus is on cardiometabolic assets, with robust financial resources and a $3–$4 billion peak revenue opportunity projected.
-
The company is transitioning to commercial operations while maintaining robust R&D, highlighted by a successful REDEMPLO launch and a strong pipeline in cardiometabolic, obesity, and CNS. Key data readouts are expected in Q3 2024, with premium pricing and gradual market adoption anticipated.
-
REDEMPLO's U.S. launch exceeded expectations, with strong prescription growth and positive payer feedback. Major pipeline milestones are expected in Q3/Q4 2026, and the company is well-funded after significant capital raises and a lucrative licensing deal with Madrigal.
-
Multiple late-stage clinical readouts, including SHASTA-3/4 and first-in-class bispecific RNA data, are expected in Q3. Commercial focus is on high-risk populations, with innovation in delivery and dimer technology driving differentiation. Ex-US strategy adapts to pricing uncertainties, while platform expansion targets new tissues and CNS indications.
-
The company is prioritizing cardiometabolic and CNS programs, with major data readouts for plozasiran and ARO-MAPT expected in 2026. Waylivra's launch for FCS has exceeded expectations, and the pipeline includes innovative obesity, liver, and lipid therapies, with a focus on premium pricing and strategic market positioning.
-
REDEMPLO received first approvals and launched in the U.S. with strong early uptake and positive payer feedback. Financials turned positive on $264M revenue, driven by licensing and milestones, and the balance sheet was significantly strengthened. Multiple late-stage readouts and launches are expected in 2026.
-
The company highlighted strong financial resources and a broad RNAi pipeline, with Rudemplo already launched for FCS and label expansion studies underway. Key programs in cardiometabolic, obesity, and CNS are advancing, with multiple clinical milestones and commercial launches expected through 2028.
-
Interim phase I/II results for ARO-INHBE and ARO-ALK7 show robust, dose-dependent reductions in visceral and liver fat, especially when combined with tirzepatide in obese diabetics, with favorable safety profiles. Both candidates are advancing to phase II, focusing on combination and maintenance therapy, targeting unmet needs in obesity and metabolic disease.
Fiscal Year 2025
-
Major milestones include the launch of Redemplo for FCS, ongoing Phase 3 studies for expanded indications, and a robust cardiometabolic pipeline. Key 2026 events are expected, including pivotal trial readouts and early data from obesity and Alzheimer's programs.
-
Major milestones include the approval and launch of Plozasiran for FCS, expansion into severe hypertriglyceridemia, and a robust pipeline in cardiometabolic, obesity, and CNS diseases. Strategic partnerships and strong cash reserves support growth and innovation.
-
Achieved first FDA approval and launch for Redemplo, driving a shift to commercial stage and supported by strong licensing revenue and cash reserves. Multiple late-stage and early-stage pipeline programs are advancing, with key data readouts and regulatory submissions expected in 2026.
-
-
Redemplo received FDA approval for FCS, with a $60,000 annual price and plans to expand into the SHTG market targeting high-risk patients. Key upcoming catalysts include phase III data for SHTG and mixed dyslipidemia, dimer and Alzheimer's data, and ongoing pipeline progress.
-
Redemplo received FDA approval as the first RNAi-based therapy for FCS, demonstrating an 80% median reduction in triglycerides and a clean safety profile. The product launches at a $60,000 annual price, with future expansion planned for high-risk SHTG patients and a robust pipeline targeting broader lipid disorders.
-
Transitioning to commercial stage with Plozasiran, the company is poised for a November launch and is advancing a broad pipeline, including SHTG, obesity, and CNS programs. Financially strong through 2028, key catalysts include multiple phase 3 readouts and new data from innovative platforms.
-
A robust RNAi pipeline is advancing with 20 clinical assets, a November PDUFA for plozasiran, and multiple phase III readouts expected in the next year. Strategic partnerships and innovative platforms in cardiometabolic, obesity, and CNS diseases position the company for significant milestones.
-
Upcoming milestones include MAPT and dimer clinical entries, a pivotal plozasiran PDUFA in November, and key obesity data by year-end. Commercial and regulatory preparations are advanced, with a strong focus on differentiation and strategic partnerships.
-
A broad RNAi pipeline is advancing toward 20 clinical or marketed candidates by 2025, with Plozasiran nearing its first PDUFA date and showing strong efficacy in FCS and SHTG. Strategic partnerships, new CNS and obesity programs, and a stepwise commercial launch are set to drive growth.
-
Reported a Q3 net loss of $175.2M with $27.8M in revenue, driven by collaboration income. Advanced four late-stage drug candidates, secured $130M upfront from Sanofi for China rights, and expects further milestone payments, supporting a cash runway into 2028.
-
Plozasiran is on track for a November launch in FCS, with strong differentiation and robust financial backing. The pipeline includes advanced SHTG trials, innovative dimer and obesity programs, and a growing CNS platform, supported by ongoing partnership strategies.
-
The platform is advancing multiple partnered and internal drug programs, with plozasiran under FDA review and three phase III studies nearing enrollment completion. Major opportunities lie in severe hypertriglyceridemia, CNS, and obesity, with business development and new data readouts expected soon.
-
Capital runway secured into 2028 supports multiple late-stage launches, with Plozasiran expected to debut for FCS this year and SHTG in 2027. Obesity and muscle programs advance, while a transformative Sarepta deal and further business development are set to extend financial flexibility.
-
A major partnership has secured financial flexibility and enabled focus on core muscle and cardiometabolic assets, with multiple product launches targeted for 2027. The pipeline includes differentiated therapies in obesity and SHTG, and new adipocyte-targeted candidates are expected next year.
-
Q2 FY2025 saw a major financial turnaround with $542.7M in revenue and $370.4M net income, driven by the Sarepta deal. Plozasiran is on track for a 2025 launch, with robust late-stage pipeline progress and strong cash reserves funding operations into 2028.
-
A transformative partnership provided capital and focus, enabling progress across rare disease, cardiometabolic, and obesity programs. Key milestones include pivotal data readouts, a potential FCS launch, and CNS pipeline expansion, with multiple clinical catalysts expected by 2026.
-
Secured $1.375B upfront from Sarepta, extending cash runway into 2028 and enabling focus on core cardiometabolic and CNS assets. Plozasiran NDA accepted by FDA with a potential late-2025 launch; multiple clinical milestones and data readouts expected in 2025.
Fiscal Year 2024
-
Announced a transformative $11B+ partnership with Sarepta, securing major upfront and milestone payments, and refocused on cardiometabolic programs with plozasiran leading toward commercial launch. Fiscal 2024 saw higher R&D spend and net loss, but the company is now funded into 2028 and positioned for multiple launches.
-
The company is advancing a broad RNAi pipeline, with a lead NDA for FCS, strong SHTG and pulmonary programs, and multiple data readouts expected in 2025. Superior efficacy and quarterly dosing differentiate its lead asset, while new CNS and obesity programs are set to enter the clinic.
-
Multiple clinical milestones are expected in the next 12 months, including NDA filing for Plozasiran, data from pulmonary, muscle, and complement programs, and the launch of obesity and CNS trials. Business development and a cardiometabolic focus are key to future growth.
-
Multiple CNS-targeted RNAi programs are advancing, with both intrathecal and systemic delivery platforms showing robust, durable target knockdown in preclinical models. The pipeline addresses diseases with high unmet need, and clinical trials for SCA2, Alzheimer's, Huntington's, and Parkinson's are progressing, with first patient dosing expected in 2025.
-
The company is advancing a diversified RNAi pipeline, prioritizing plozasiran for near-term commercialization following strong phase III results. Financial strategy leverages multiple capital sources, with a goal of cash flow positivity as commercial launches begin. Initial lung program data are expected by year-end.
-
A strategic portfolio review led to focused R&D investment in plozasiran, with proactive business development to manage a robust pipeline. Recent phase III data for plozasiran in FCS showed strong efficacy and safety, supporting a 2025 launch and future expansion into larger indications.
-
Obesity is now seen as a complex, multi-disease condition needing diverse treatments. Two new RNAi therapies, ARO-INHBE and ARO-ALK7, target the liver-adipose axis to reduce fat while preserving muscle, with clinical trials set to start soon and initial data expected in 2025.
-
Q3 2024 saw strong progress on plozasiran, with positive phase III results in FCS and a $500M credit facility secured to fund growth. Net loss widened due to higher R&D, but liquidity was bolstered by new financing and a $50M milestone payment.
-
The pulmonary RNAi platform is advancing three clinical programs targeting inflammation, mucus, and fibrosis in major lung diseases. ARO-RAGE has shown deep target engagement and safety, with phase II in severe asthma planned for 2025. ARO-MUC5AC and ARO-MMP7 are enrolling patients, with key data expected in 1H 2025.
-
Plozasiran is prioritized for development due to strong efficacy in reducing triglycerides and ApoC-III across FCS, SHTG, and mixed hyperlipidemia, with a favorable safety profile and large market potential. Ongoing phase III studies and a cardiovascular outcome trial are underway, with a 2025 launch targeted. Zodasiran may be partnered out, and new obesity/metabolic programs are advancing.
-
Phase III data for plozasiran showed strong triglyceride and APOC3 reductions, with further efficacy and patient outcome data expected later this year. Pulmonary and complement programs are advancing, with key patient data anticipated by year-end. Financing strategy remains diversified and focused on future commercial revenue.
-
The company highlighted strong phase 3 results for plozasiran, significant market opportunities in FCS and SHTG, and a robust pipeline across cardiometabolic, pulmonary, and muscle indications. Key catalysts include upcoming data readouts and the first commercial launch targeted for next year.